Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
Clare BuckeridgeNikolaos TsamandourasSantos Carvajal-GonzalezLisa S BrownMartha Hernandez-IllasAditi R SaxenaPublished in: Diabetes, obesity & metabolism (2024)
gov identifier: NCT04305587, NCT05158244.
Keyphrases
- placebo controlled
- type diabetes
- small molecule
- double blind
- insulin resistance
- phase iii
- phase ii
- study protocol
- clinical trial
- glycemic control
- metabolic syndrome
- protein protein
- weight loss
- phase ii study
- case control
- physical activity
- cardiovascular disease
- high fat diet induced
- open label
- weight gain
- pulmonary artery
- randomized controlled trial
- aortic dissection
- skeletal muscle
- radiation therapy
- adipose tissue
- squamous cell carcinoma
- pulmonary arterial hypertension